The THRombolysis and STatins (THRaST) study

Objective: To assess the impact on stroke outcome of statin use in the acute phase after IV thrombolysis. Methods: Multicenter study on prospectively collected data of 2,072 stroke patients treated with IV thrombolysis. Outcome measures of efficacy were neurologic improvement (NIH Stroke Scale [NIHSS] <= 4 points from baseline or NIHSS = 0) and major neurologic improvement (NIHSS <= 8 points from baseline or NIHSS = 0) at 7 days and favorable (modified Rankin Scale [mRS] <= 2) and excellent functional outcome (mRS <= 1) at 3 months. Outcome measures of safety were 7-day neurologic deterioration (NIHSS >= 4 points from baseline or death), symptomatic intracerebral hemorrhage type 2 with NIHSS >= 4 points from baseline or death within 36 hours, and 3-month death. Results: Adjusted multivariate analysis showed that statin use in the acute phase was associated with neurologic improvement (odds ratio [OR] 1.68, 95% confidence interval [CI] 1.26-2.25; p < 0.001), major neurologic improvement (OR 1.43, 95% CI 1.11-1.85; p = 0.006), favorable functional outcome (OR 1.63, 95% CI 1.18-2.26; p = 0.003), and a reduced risk of neurologic deterioration (OR: 0.31, 95% CI 0.19-0.53; p < 0.001) and death (OR 0.48, 95% CI 0.28-0.82; p = 0.007). Conclusion: Statin use in the acute phase of stroke after IV thrombolysis may positively influence short-and long-term outcome. Neurology (R) 2013;80:655-661